Tags

Type your tag names separated by a space and hit enter

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.

Abstract

INTRODUCTION

Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).

AIM

To assess the efficacy and safety of flibanserin over 24 weeks of double-blind treatment vs. placebo in premenopausal women with HSDD who showed a predefined response after 24 weeks of open-label treatment with flibanserin.

METHODS

Women (N = 738) were treated with open-label, flexible-dose flibanserin (50 mg or 100 mg/day) for 24 weeks. At week 24, women who showed a predefined response, measured using an eDiary, were randomized to 24 weeks of continued flibanserin therapy at optimized dosage (N = 163) or placebo (N = 170). The criteria for entering the double-blind phase were an increase from baseline to weeks 21-24 of ≥2 satisfying sexual events (SSE) and/or ≥4 "desire days." A "desire day" was one in which a woman reported more than "no" desire.

MAIN OUTCOME MEASURES

Coprimary endpoints were change from randomization to study end in SSE and desire score. Secondary measures included change in Female Sexual Function Index (FSFI) total and desire domain scores and Female Sexual Distress Scale-Revised (FSDS-R) total and Item 13 scores.

RESULTS

During the open-label period, mean SSE and desire score approximately doubled, and FSFI, FSDS-R total, and Item 13 scores improved. At the end of the double-blind period, flibanserin was superior to placebo in change from randomization in SSE, desire score, FSFI desire domain and total scores, and FSDS-R total and Item 13 scores (P < 0.05, for all). Flibanserin was well tolerated, and withdrawal reactions were not observed.

CONCLUSIONS

At the end of the 24-week randomized withdrawal phase of a 48-week trial in premenopausal women with HSDD, flibanserin was superior to placebo on measures of SSE, sexual desire, overall sexual function, and sexual distress. Flibanserin was well tolerated, and no withdrawal reactions were observed following discontinuation.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Hudson Valley Urology, Poughkeepsie, New York, NY 12601, USA. evanrgold@gmail.com

    , , , , , ,

    Source

    The journal of sexual medicine 8:11 2011 Nov pg 3160-72

    MeSH

    Adult
    Benzimidazoles
    Double-Blind Method
    Female
    Humans
    Libido
    Serotonin 5-HT1 Receptor Agonists
    Serotonin 5-HT2 Receptor Antagonists
    Sexual Dysfunctions, Psychological
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    21933348

    Citation

    Goldfischer, Evan R., et al. "Continued Efficacy and Safety of Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD): Results From a Randomized Withdrawal Trial." The Journal of Sexual Medicine, vol. 8, no. 11, 2011, pp. 3160-72.
    Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. J Sex Med. 2011;8(11):3160-72.
    Goldfischer, E. R., Breaux, J., Katz, M., Kaufman, J., Smith, W. B., Kimura, T., ... Pyke, R. (2011). Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. The Journal of Sexual Medicine, 8(11), pp. 3160-72. doi:10.1111/j.1743-6109.2011.02458.x.
    Goldfischer ER, et al. Continued Efficacy and Safety of Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD): Results From a Randomized Withdrawal Trial. J Sex Med. 2011;8(11):3160-72. PubMed PMID: 21933348.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. AU - Goldfischer,Evan R, AU - Breaux,Jeffery, AU - Katz,Molly, AU - Kaufman,Joel, AU - Smith,William B, AU - Kimura,Toshio, AU - Sand,Michael, AU - Pyke,Rob, Y1 - 2011/09/20/ PY - 2011/9/22/entrez PY - 2011/9/22/pubmed PY - 2012/3/1/medline SP - 3160 EP - 72 JF - The journal of sexual medicine JO - J Sex Med VL - 8 IS - 11 N2 - INTRODUCTION: Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD). AIM: To assess the efficacy and safety of flibanserin over 24 weeks of double-blind treatment vs. placebo in premenopausal women with HSDD who showed a predefined response after 24 weeks of open-label treatment with flibanserin. METHODS: Women (N = 738) were treated with open-label, flexible-dose flibanserin (50 mg or 100 mg/day) for 24 weeks. At week 24, women who showed a predefined response, measured using an eDiary, were randomized to 24 weeks of continued flibanserin therapy at optimized dosage (N = 163) or placebo (N = 170). The criteria for entering the double-blind phase were an increase from baseline to weeks 21-24 of ≥2 satisfying sexual events (SSE) and/or ≥4 "desire days." A "desire day" was one in which a woman reported more than "no" desire. MAIN OUTCOME MEASURES: Coprimary endpoints were change from randomization to study end in SSE and desire score. Secondary measures included change in Female Sexual Function Index (FSFI) total and desire domain scores and Female Sexual Distress Scale-Revised (FSDS-R) total and Item 13 scores. RESULTS: During the open-label period, mean SSE and desire score approximately doubled, and FSFI, FSDS-R total, and Item 13 scores improved. At the end of the double-blind period, flibanserin was superior to placebo in change from randomization in SSE, desire score, FSFI desire domain and total scores, and FSDS-R total and Item 13 scores (P < 0.05, for all). Flibanserin was well tolerated, and withdrawal reactions were not observed. CONCLUSIONS: At the end of the 24-week randomized withdrawal phase of a 48-week trial in premenopausal women with HSDD, flibanserin was superior to placebo on measures of SSE, sexual desire, overall sexual function, and sexual distress. Flibanserin was well tolerated, and no withdrawal reactions were observed following discontinuation. SN - 1743-6109 UR - https://www.unboundmedicine.com/medline/citation/21933348/Continued_efficacy_and_safety_of_flibanserin_in_premenopausal_women_with_Hypoactive_Sexual_Desire_Disorder__HSDD_:_results_from_a_randomized_withdrawal_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1743-6095(15)33306-3 DB - PRIME DP - Unbound Medicine ER -